Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Alexander

Showing results (961-970 of 1,212) with videos related to

Pageof 122
Sort By:
The Lancet. Neurology|May 11, 2012
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialJ Donald Easton, Renato D Lopes, M Cecilia Bahit, et al.
British Journal of Pharmacology|November 12, 2019
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptorsStephen P H Alexander, John A Cidlowski, Eamonn Kelly, et al.
International Journal of Cardiology|November 7, 2013
Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trialMaria Cecilia Bahit, Renato D Lopes, Daniel M Wojdyla, et al.
Open Heart|March 20, 2021
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areasTymon Pol, Ziad Hijazi, Johan Lindbäck, et al.
American Heart Journal|September 24, 2016
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarctionC Michael Gibson, Serge Korjian, Pierluigi Tricoci, et al.
The Journal of Invasive Cardiology|November 5, 2013
Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trialJohn P Vavalle, Thomas J Povsic, Laura H Aberle, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 24, 2019
Second nationwide anti-tuberculosis drug resistance survey in NamibiaN Ruswa, F Mavhunga, J C Roscoe, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 10, 2017
Secondary surgical-site infection after coronary artery bypass grafting: A multi-institutional prospective cohort studyBrian C Gulack, Katherine A Kirkwood, Wei Shi, et al.
JAMA|April 3, 2008
Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial, John H Alexander, Robert W Emery, et al.
The American Journal of Medicine|December 29, 2010
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic TherapyRajendra H Mehta, Amanda Stebbins, Renato D Lopes, et al.
Pageof 122

Showing results (961-970 of 1,212) with videos related to

Sort By:
Pageof 122
The Lancet. Neurology|May 11, 2012
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialJ Donald Easton, Renato D Lopes, M Cecilia Bahit, et al.
British Journal of Pharmacology|November 12, 2019
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptorsStephen P H Alexander, John A Cidlowski, Eamonn Kelly, et al.
International Journal of Cardiology|November 7, 2013
Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trialMaria Cecilia Bahit, Renato D Lopes, Daniel M Wojdyla, et al.
Open Heart|March 20, 2021
Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areasTymon Pol, Ziad Hijazi, Johan Lindbäck, et al.
American Heart Journal|September 24, 2016
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarctionC Michael Gibson, Serge Korjian, Pierluigi Tricoci, et al.
The Journal of Invasive Cardiology|November 5, 2013
Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trialJohn P Vavalle, Thomas J Povsic, Laura H Aberle, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 24, 2019
Second nationwide anti-tuberculosis drug resistance survey in NamibiaN Ruswa, F Mavhunga, J C Roscoe, et al.
The Journal of Thoracic and Cardiovascular Surgery|December 10, 2017
Secondary surgical-site infection after coronary artery bypass grafting: A multi-institutional prospective cohort studyBrian C Gulack, Katherine A Kirkwood, Wei Shi, et al.
JAMA|April 3, 2008
Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial, John H Alexander, Robert W Emery, et al.
The American Journal of Medicine|December 29, 2010
Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic TherapyRajendra H Mehta, Amanda Stebbins, Renato D Lopes, et al.
Pageof 122